UPDATE: Credit Suisse Assumes Durata Therapeutics at Outperform on Valuation, Derisking

Credit Suisse assumed coverage on Durata Therapeutics

with an Outperform rating and a $15.00 price target. Credit Suisse analyst Jason Kantor commented, "Our continued positive thesis has three main components (1) dalbavancin is substantially derisked; (2) the market opportunity is large and fragmented, and even a small percentage share could drive sales greater than $250M in the United States; and (3) DRTX has the lowest cost structure in the industry, maximizing the potential for profit, even as sales ramp in early years. These factors are made more compelling by the low valuation." Durata Therapeutics closed at $8.25 on Thursday.